CClinicalTrials.gg
RecruitingNCT06012799Updated Apr 17, 2024

Continuous Glucose Monitoring in Peri-operative Period in Kidney Transplant Recipients

An observational study in New Onset Diabetes After Transplantation, sponsored by Seoul National University Hospital. Recruiting at 1 site in Korea, Republic of. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-04-17.

Sponsored by Seoul National University Hospital · Observational

From the registry’s dates

  • Primary completion was expected by Sep 2024, 2 years ago, but the record still lists the study as recruiting.
  • Started May 2021; still recruiting 5 years 4 months later.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
100
Ages
18 Years and older
Sex
All
01

Study summary

his study aims to utilize Continuous Glucose Monitoring (CGM) to observe glucose fluctuations in kidney transplant recipients and predict New-Onset Diabetes After Transplantation (NODAT) based on these patterns. Additionally, it seeks to investigate glucose variability resulting from medications and surgeries such as immunosuppressants and steroid regimens post-kidney transplantation. This prospective observational study anticipates identifying factors influencing blood glucose levels and contributing to future research on blood glucose management using CGM monitoring in kidney transplant patients.

02

Conditions studied

  • New Onset Diabetes After Transplantation
03

In context

Lead sponsor

Seoul National University Hospital is the lead sponsor of 1,860 studies on the registry; 275 are open to participants now.

Of its 12 completed or terminated interventional studies of FDA-regulated products, 2 (17%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Sampling method
Non-probability sample

Study population

Kidney transplant patients

Inclusion criteria

  • The study will target 100 kidney transplant patients who have provided consent, among those who underwent the procedure at Seoul National University Hospital after March 2021.

Exclusion criteria

Exclusion Criteria:

  • multi-organ transplant
  • history of previous kidney transplant
  • less than 18 years old
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
100 participants (estimated)
Patient registry
No

Interventions

  • Diagnostic testcontinuous glucose monitoring

    FreeStyle Libre Flash Glucose Monitoring System

06

What researchers measure

Primary outcomes

  1. Rate of NODAT

    rate of new onset diabetes after transplantation

    Time frame: 6 months after kidney transplantation

07

Study locations

1 of 1 sites recruiting
  • Seoul National University Hospital
    Seoul, 110-744, Korea, Republic of
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 17, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06012799
Lead sponsor
Seoul National University Hospital
Responsible party
Sponsor
First posted
Aug 25, 2023
Start date
May 15, 2021
Primary completion
Sep 30, 2024 (estimated)
Completion
Dec 30, 2024 (estimated)
Last update
Apr 17, 2024

Study contacts

Jiyoung Sin, MD
Contact
taddy11119@gmail.com
82-10-6593-6503

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion